“The Triple Threat”
A triple-receptor agonist still in clinical trials, appetite suppression can show up as early as the first dose, with weight change following faster than almost anything else in this list.
Retatrutide activates three separate metabolic receptors at once: GLP-1, GIP, and glucagon, which together suppress appetite, slow digestion, and increase energy expenditure. Hitting all three pathways simultaneously is what sets it apart from single- or dual-receptor drugs.
No. It's currently in Phase 3 clinical trials and not yet approved or commercially available.
Phase 2 trial data reported around 24% average weight loss at the highest dose over 48 weeks, among the largest effects reported for this drug class so far.
It's being studied in structured clinical trials with monitored dosing, which is different from how it's typically obtained outside that context. Side effects reported in trials are broadly similar to other GLP-1-class drugs, mainly nausea and GI symptoms.
Retatrutide has one of the strongest human clinical trial datasets of any peptide in this library, even though it isn't approved yet. It's a genuine glimpse at where GLP-1-class drugs are headed next.
Everything on this page, plus the exact reconstitution math, dosing progression, cycle length, and every warning sign, in one focused guide.
A focused, start-to-finish guide built around Retatrutide specifically. No filler, no padding, just what you need.
Get The Protocol · $10